Synapse - Works

Results (2841)

Post-transplant cyclophosphamide is associated with improved clinical outcomes in HLA-mismatched unrelated donor hematopoietic cell transplantation

Meeting Abstract

Jimenez, A. M.; Perales, M. A.; Devlin, S. M.; Lekakis, L. J.; Sauter, C. S.; Pereira, D.; Beitinjaneh, A.; Brown, S.; Wang, T.; Ponce, D. M.; more...
Blood (2021)

Fulltext@MSK | Save

Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade

Meeting Abstract

Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
Blood (2021)

Fulltext@MSK | Save

Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study

Meeting Abstract

Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
Blood (2021)

Fulltext@MSK | Save

Prognostic value of minimal residual disease (MRD) among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation

Meeting Abstract

Taranto, E.; Redd, R. A.; Jeter, E.; McHugh, K. M.; Brown, J. R.; Crombie, J. L.; Davids, M. S.; Fisher, D. C.; Freedman, A. S.; Jacobsen, E. D.; more...
Blood (2021)

Fulltext@MSK | Save

Timing and immune status after cellular therapies predict response to COVID-19 vaccines

Meeting Abstract

Tamari, R.; Politikos, I.; Knorr, D.; Vardhana, S.; Young, J.; Marcello, L.; Doddi, S.; Devlin, S. M.; Ramanathan, L.; Pessin, M. S.; more...
Blood (2021)

Fulltext@MSK | Save

Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center

Meeting Abstract

Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
Blood (2021)

Fulltext@MSK | Save

Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures

Meeting Abstract

Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
Blood (2021)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save

CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study

Meeting Abstract

Patel, K.; Zonder, J. A.; Sano, D.; Maris, M.; Lesokhin, A.; von Keudell, G.; Lai, C.; Ramchandren, R.; Catalano, T.; Lin, G. H. Y.; more...
Blood (2021)

Fulltext@MSK | Save